These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25989246)

  • 1. Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials.
    Graudal N; Hubeck-Graudal T; Faurschou M; Baslund B; Jürgens G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1487-95. PubMed ID: 25989246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
    Graudal N; Hubeck-Graudal T; Tarp S; Christensen R; Jürgens G
    PLoS One; 2014; 9(9):e106408. PubMed ID: 25244021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis therapy in combination with TNF-α inhibitor and DMARDs: A multitarget method for the treatment of rheumatoid arthritis.
    Cheng Y; Yang F; Huang C; Huang J; Wang Q; Chen Y; Du Y; Zhao L; Gao M; Wang F
    Mod Rheumatol; 2017 Jul; 27(4):576-581. PubMed ID: 27830969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.
    Ma MH; Kingsley GH; Scott DL
    Rheumatology (Oxford); 2010 Jan; 49(1):91-8. PubMed ID: 19917618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
    Wells AF; Curtis JR; Betts KA; Douglas K; Du EX; Ganguli A
    Clin Ther; 2017 Aug; 39(8):1680-1694.e2. PubMed ID: 28734661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
    Callhoff J; Weiß A; Zink A; Listing J
    Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.